Navigation Links
Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast'
Date:8/10/2011

an volunteers treated with Revamilast suggests a good ex-vivo inhibition of the inflammatory marker TNF-α with maximum inhibition upto 93%. Based on these results and animal model data, it is expected that Revamilast would be beneficial in a variety of inflammatory disorders. Additionally, Revamilast does not appear to be metabolized to carcinogenic metabolites (ADCP N-oxide and ADCP N-oxide epoxide); and plasma samples from a Phase 1 study analyzed for such metabolites of Revamilast, showed no levels were detected in human plasma.

With the completion of several Phase I studies, Glenmark has initiated a global Phase IIb trial for Revamilast in patients with Asthma. Glenmark has already received approval from respective authorities in the UK, Poland, India and Czech Republic to conduct Phase IIb studies. Regulatory submissions have also been completed in Russia. The primary objective of this 12-week, double blind, placebo controlled, dose range finding study is to evaluate the effects of Revamilast at three doses on lung function (FEV1) in nearly 450 patients with chronic persistent Asthma.

Glenmark has also initiated another global Phase IIb trial with Revamilast in patients with Rheumatoid Arthritis. Glenmark has already received approval from the MHRA, UK, India, Poland and the Philippines to conduct Phase IIb studies for Rheumatoid Arthritis. Regulatory submissions have also been completed in Sri Lanka. The objective is to determine the efficacy of three doses of Revamilast compared to placebo in the treatment of more than 400 patients with active Rheumatoid Arthritis who showed an inadequate response to methotrexate.

In parallel to these two clinical studies, Glenmark is also conducting various other clinical and non-clinical studies to ensure timely entry into Phase III trials. Glenmark intends to initiate Phase III trials for at least one indication in the second half of FY 2012-13

PDE4 inhibitors (Impact o
'/>"/>

SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Glenmark Announces the Discovery of a Novel Chemical Entity GRC 17536, a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally
2. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
3. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
4. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
5. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
6. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
7. GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine
8. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
9. Metabolex Initiates Phase 2 Trial of Arhalofenate
10. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
11. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... September 30, 2014 Award winning ... announces four new-hosted collaboration bundles that combine ... high quality conferencing experiences for low, flat rate ... choose from, businesses have optimized solutions to meet ... include audio only minutes (1K, 5K, 10K ...
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
(Date:9/30/2014)... , Sept. 30, 2014 Pacific Northwest ... Summary Global Markets Direct,s, ,Pacific Northwest ... provides an overview of the Pacific Northwest Biotechnology, ... report provides comprehensive information on the current therapeutic ... with comparative analysis at various stages, therapeutics assessment ...
(Date:9/30/2014)... Proove Biosciences , the commercial ... announce a new genetic test built upon research from ... Test will provide physicians with an objective way ... levels are stratified between individuals. With this new test, ... has a genetic predisposition that will affect their pain ...
Breaking Biology Technology:SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... Inc. (Nasdaq: SNUS ) today announced that it ... on July 16,2008 indicating that the NASDAQ Panel has ... its securities on The NASDAQ Global,Market. The Company,s continued ... conditions by August 29, 2008, including the,implementation of a ...
... (NYSE:,LDR), will release financial results for the fiscal ... 2008., The company will host a conference ... 2:00 p.m. Eastern Time. Investors may access the ... and Canada), or 303-262-2137,(international callers), or by visiting ...
... July 17 Silence Therapeutics plc (London AIM:,SLN), ... that,for personal reasons, Jeffery Vick has resigned as ... of Directors has appointed Iain Ross, currently Non-Executive,Chairman, ... effect. Jeremy,Curnock Cook, a Non-Executive Director of the ...
Cached Biology Technology:Sonus Pharmaceuticals Receives Favorable NASDAQ Decision 2Sonus Pharmaceuticals Receives Favorable NASDAQ Decision 3Organizational Changes at Silence Therapeutics 2Organizational Changes at Silence Therapeutics 3
(Date:9/30/2014)... HONG KONG , Sept. 30, 2014 Winners of ... The Economist Events, Innovation Summit scheduled to take place at the ... At the summit, the award winners will share their experiences and ... people who have made a proven innovation over the past decade, ... the night before the summit. It will be the ...
(Date:9/29/2014)... 1970 and 2010 populations of mammals, birds, reptiles, ... percent, says the 2014 Living Planet Report released ... loss occurs disproportionately in low-income countriesand correlates with ... In addition to the precipitous decline in wildlife ... signs about the overall health of the planet. ...
(Date:9/29/2014)... Texas at Arlington research team says recently identified radiation ... lab could open doors for homeland security and medical ... the Oct. 1 issue of Optics Letters , ... describe a new method to fabricate transparent nanoscintillators by ... a transparent ceramic is formed. A scintillator refers ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Half of global wildlife lost, says new WWF report 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... French . An international research team ... As a result, the researchers recommend that clinical trials on ... New England Journal of Medicine in an article ... Research Institute of the McGill University Health Centre (RI-MUHC). ...
... more than $29 million for the University of California, ... former gold mine in South Dakota into the world,s ... the National Science Board, is for a preliminary design ... a facility at the former Homestake gold mine in ...
... newly recognized pest in Oregon continues to concern fruit growers ... Drosophila fly in a sample of Willamette Valley ... , was first confirmed in Oregon less than two months ... its occurrence in a variety of fresh fruits, including blueberries, ...
Cached Biology News:Research shows treating HIV-AIDS with interleukin-2 is ineffective 2NSF authorizes $29 million for preliminary design of world's deepest underground laboratory 2NSF authorizes $29 million for preliminary design of world's deepest underground laboratory 3Fruit fly pest identified in wine grapes 2Fruit fly pest identified in wine grapes 3Fruit fly pest identified in wine grapes 4
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
... pressure gradient system uses three Adept CE ... a flow rate in one microlitre increaments. ... added flexibility. System control and data processing ... interface unit, CE 4900., Column heater/chillers can be ...
... of large numbers of samples may be carried ... minimum operator attention. System control and data ... CE 4900. The elegant, powerful and very ... and Windows 98 and 2000., The supplied detector ...
Biology Products: